Valsartan NDMA Blood Pressure Drug Cancer Lawsuit MDL 2875: 2026 Claimant Guide
Disclaimer: This post is for general information only and not legal advice. Consult a licensed US attorney for your specific situation.
What Is Valsartan and Why Were Millions Exposed?
Valsartan is an angiotensin receptor blocker (ARB) — a class of medications widely prescribed for high blood pressure (hypertension) and heart failure. The branded version Diovan (manufactured by Novartis) was one of the world’s best-selling medications; dozens of generic versions became available after the patent expired in 2012.
Across the US, millions of patients take valsartan or related ARBs daily as part of their cardiovascular management. These patients trusted that their medications were safe — that decades of manufacturing standards and FDA oversight guaranteed quality.
In the summer of 2018, that trust was shattered.
The 2018 Discovery: A Manufacturing Process Change With Deadly Consequences
Zhejiang Huahai and the API Supply Chain
The valsartan contamination story begins in Linhai, Zhejiang Province, China, at the facilities of Zhejiang Huahai Pharmaceutical (ZHP). ZHP was a major global supplier of the active pharmaceutical ingredient (API) used in valsartan products sold worldwide — including to major US generic manufacturers.
Seeking to improve efficiency, ZHP implemented a manufacturing process change. This change introduced chemical reactions that generated NDMA (N-nitrosodimethylamine) as an unintended and undetected byproduct in the valsartan API.
The contaminated API was then shipped to US manufacturers — primarily Mylan, Teva, Aurobindo, Hetero, and others — who processed it into finished valsartan tablets and capsules sold to American patients. Patients had no way to know their medication contained a probable carcinogen.
Scale of the Contamination
| Metric | Data |
|---|---|
| FDA-tracked recalled lots | 1,246 lots of valsartan products (2018–2021) |
| International scope | ~2,300 batches recalled in 22 countries |
| Primary API source | Zhejiang Huahai Pharmaceutical |
| Also affected | Losartan and irbesartan products from multiple manufacturers |
NDMA and NDEA: Why These Chemicals Are Dangerous
NDMA (N-nitrosodimethylamine) and NDEA (N-nitrosodiethylamine) are nitrosamine compounds classified by the International Agency for Research on Cancer (IARC) as probable human carcinogens (Group 2A).
Key distinction from Zantac’s NDMA: While ranitidine generates NDMA intrinsically through molecular degradation, valsartan’s NDMA was an external manufacturing process impurity — caused by a specific, identifiable chemical reaction in the manufacturing process. This distinction matters both scientifically and legally.
Cancer Risk Quantification
FDA’s risk analysis estimated that patients taking the highest contaminated dose of valsartan (320mg/day) for seven years faced an additional cancer risk of approximately 1 in 5,000 patients. At first glance this appears low — but given that millions of people took contaminated valsartan, the estimated population-level impact is significant.
MDL 2875: The Federal Litigation
Case Overview
- Full case name: In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, MDL No. 2875
- Court: U.S. District Court, District of New Jersey
- Judge: Robert B. Kugler
- Defendants: Zhejiang Huahai Pharmaceutical; Mylan Pharmaceuticals; Teva Pharmaceuticals; Aurobindo Pharma; Hetero Labs; Torrent Pharmaceuticals; and others
Core Legal Theories
| Theory | Basis |
|---|---|
| Strict products liability (defective product) | Contaminated valsartan was not the safe medication it was represented to be |
| Failure to warn | Defendants knew or should have known of contamination and failed to warn |
| Negligence | Failure to maintain adequate manufacturing quality controls |
| Fraud/misrepresentation | Marketing the product as safe when it contained carcinogens |
Challenges: Foreign Defendant and Supply Chain Complexity
Suing Zhejiang Huahai Pharmaceutical — a Chinese company — presents procedural challenges including service of process under the Hague Convention and sovereign/corporate immunity arguments. However, the US-based manufacturers (Mylan, Teva, Aurobindo) are fully subject to US jurisdiction, and plaintiffs have pursued claims against all parties in the supply chain.
Recalled Drugs: Valsartan, Losartan, and Irbesartan
MDL 2875 covers three ARB medications:
| Drug | Brand Example | Primary Contamination | Key Recalled Manufacturers |
|---|---|---|---|
| Valsartan | Diovan (generic) | NDMA | Zhejiang Huahai, Mylan, Teva |
| Losartan | Cozaar (generic) | NDMA, NDEA | Aurobindo, Hetero, Torrent |
| Irbesartan | Avapro (generic) | NDMA | Various manufacturers |
Cancer Types Most Frequently Alleged
| Cancer Type | Connection to NDMA Exposure |
|---|---|
| Liver cancer (hepatocellular carcinoma) | NDMA primarily metabolized in the liver |
| Stomach/gastric cancer | Oral ingestion route; gastric mucosa exposure |
| Kidney cancer | Renal excretion pathway |
| Lung cancer | Systemic distribution through bloodstream |
| Colorectal cancer | Gastrointestinal tract exposure |
| Bladder cancer | Urinary excretion |
Who May Have a Valsartan Claim?
Eligibility Criteria
| Criterion | Details |
|---|---|
| Drug use | Documented prescription of recalled valsartan, losartan, or irbesartan |
| Manufacturer | Made by Zhejiang Huahai, Mylan, Teva, Aurobindo, Hetero, Torrent, or other recalled manufacturer |
| Lot number | Ideally traceable to a recalled lot (FDA database) |
| Cancer diagnosis | Liver, stomach, kidney, lung, colorectal, or other relevant cancer |
| Duration | Typically longer-term use supports stronger causal arguments |
| Statute of limitations | Not expired |
Statute of Limitations by State
| State | Products Liability SOL | Discovery Rule |
|---|---|---|
| New Jersey | 2 years | Yes |
| California | 2 years | Yes |
| New York | 3 years | Yes |
| Texas | 2 years | Limited |
| Florida | 2 years | Yes |
| Illinois | 2 years | Yes |
| Pennsylvania | 2 years | Yes |
| Ohio | 2 years | Yes |
The July 2018 recall was extensively covered in major news media. Courts may find that patients had constructive knowledge of the contamination starting in July 2018. For patients diagnosed with cancer in 2018 or 2019, 2-year deadlines may have passed in many states. Consult an attorney immediately if you believe you have a claim.
Hypothetical Claimant Scenarios
Scenario 1: Liver Cancer, Long-Term Valsartan Use
Profile: William, 67, took Mylan-manufactured generic valsartan 320mg daily from 2014 to 2018. His pharmacy confirmed the lots dispensed were among those recalled. He was diagnosed with hepatocellular carcinoma (liver cancer) in March 2019.
Analysis: Recalled product confirmed; long-term use; liver cancer (primary NDMA metabolic pathway); March 2019 diagnosis. Under most states’ 2-year SOL from diagnosis: deadline March 2021. If a claim was not filed by then, the discovery rule argument must be evaluated — when did William meaningfully connect his medication to his cancer? Attorney consultation urgently needed.
Scenario 2: Kidney Cancer, Aurobindo Losartan
Profile: Patricia, 61, took Aurobindo-manufactured losartan 100mg from 2015 to 2019. Diagnosed with kidney cancer in October 2021.
Analysis: Losartan is within MDL 2875 scope; Aurobindo is a named defendant. October 2021 diagnosis + 2-year SOL = deadline October 2023 in most states. If not already filed, this may have passed — but the discovery rule should be evaluated. Immediate attorney consultation.
Scenario 3: Medical Monitoring Without Cancer Diagnosis
Profile: Robert, 59, took recalled Teva valsartan from 2013 to 2018 and has no cancer diagnosis but wants to monitor his health due to NDMA exposure.
Analysis: Some MDL cases include medical monitoring class claims for patients without cancer. Recovery amounts are lower and the legal standard varies by state, but some courts have recognized medical monitoring as a legitimate remedy. An attorney can evaluate whether this path is viable in Robert’s state.
How to Check If Your Medication Was Recalled
- FDA drug recalls database: www.fda.gov/drugs/drug-safety-and-availability/recalls-market-withdrawals-safety-alerts — search “valsartan”
- Lot number verification: Check your prescription bottle’s lot number against the FDA’s recalled lot database
- Pharmacy records: Ask your pharmacy to pull dispensing records and check whether the lots dispensed to you were recalled
- Attorney assistance: Mass tort attorneys can help locate and verify lot numbers
Related Articles
- Zantac Ranitidine Cancer Lawsuit MDL 2924
- Paraquat Parkinson’s Disease Lawsuit Guide
- Roundup Non-Hodgkin’s Lymphoma Lawsuit
- Talcum Powder Ovarian Cancer Lawsuit Guide
- Asbestos Trust Fund Claims for Veterans
Key Takeaways
- MDL 2875 (In re: Valsartan, Losartan, and Irbesartan) is in the D. New Jersey before Judge Robert B. Kugler.
- July 2018 recall triggered by NDMA contamination from a manufacturing process change at Zhejiang Huahai Pharmaceutical (China).
- FDA tracked 1,246 recalled lots across 2018–2021; 22 countries recalled ~2,300 batches.
- Key defendants: Zhejiang Huahai (China), Mylan, Teva, Aurobindo, Hetero, Torrent.
- Cancer types claimed: liver, stomach, kidney, lung, colorectal cancer.
- Statutes of limitations are likely running — patients diagnosed in 2018–2019 may face expired deadlines. Act immediately.
Disclaimer: This post is for general information only and not legal advice. Consult a licensed US attorney for your specific situation.
What court handles MDL 2875 valsartan litigation?
MDL 2875 — In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation — is centralized in the U.S. District Court for the District of New Jersey before Judge Robert B. Kugler. Verify current docket status on PACER.
When did the valsartan recall happen and why?
In July 2018, the FDA announced recalls of valsartan products after NDMA contamination was discovered in batches manufactured by Zhejiang Huahai Pharmaceutical in China. The FDA tracked 1,246 lots of valsartan across recalls from 2018–2021; 22 countries recalled approximately 2,300 batches worldwide. The contamination was traced to a manufacturing process change that generated NDMA as an unintended byproduct.
What are NDMA and NDEA?
NDMA (N-nitrosodimethylamine) and NDEA (N-nitrosodiethylamine) are classified by the International Agency for Research on Cancer (IARC) as probable human carcinogens (Group 2A). Unlike the Zantac situation (intrinsic molecular instability), the valsartan NDMA contamination was caused by an external manufacturing process impurity.
What cancers are claimed in valsartan lawsuits?
Liver cancer, stomach cancer, kidney cancer, lung cancer, and colorectal cancer are the primary cancer types alleged. FDA's risk analysis estimated contaminated valsartan could cause one additional cancer per 5,000 patients taking the highest dose daily for seven years.
Who are the defendants in MDL 2875?
Primary defendants include Zhejiang Huahai Pharmaceutical (Chinese API manufacturer), Mylan Pharmaceuticals, Teva Pharmaceuticals, Aurobindo Pharma, Hetero Labs, and Torrent Pharmaceuticals, among others.
Is the valsartan MDL still active in 2026?
MDL 2875 continues in New Jersey federal court with ongoing proceedings including bellwether trials, individual settlements with some defendants, and continued processing of remaining claims. Verify current status via PACER or a qualified attorney.
How do I know if my blood pressure medication was recalled?
Check the FDA's valsartan recall database at fda.gov. Look for your drug's manufacturer name (Zhejiang Huahai, Mylan, Teva, Aurobindo, Hetero, Torrent) and lot number. Ask your pharmacy to check whether your dispensed lots were recalled. A mass tort attorney can also assist with this verification.
What is the statute of limitations for valsartan cancer claims?
Most states allow 2–3 years from cancer diagnosis or from when you knew or should have known of the valsartan contamination. The July 2018 recall received widespread media coverage — courts may find that patients diagnosed after July 2018 should have connected contamination to their cancer by 2020 or 2021. Consult an attorney immediately.
Does losartan or irbesartan contamination also qualify?
Yes. MDL 2875 covers valsartan, losartan, and irbesartan NDMA/NDEA contamination claims. Losartan products from multiple manufacturers (including Aurobindo and Hetero) and irbesartan products were also recalled and are included in the MDL.
What is the difference between valsartan contamination and Zantac's NDMA issue?
Valsartan's NDMA came from an external manufacturing process impurity — a specific chemical reaction triggered by a process change at Zhejiang Huahai. Ranitidine (Zantac) generates NDMA intrinsically through molecular instability regardless of manufacturing. These are fundamentally different mechanisms with different legal implications.
관련 글
Zantac Ranitidine Cancer Lawsuit MDL 2924: What Claimants Need to Know in 2026
Asbestos Trust Fund Claims for US Navy Veterans With Mesothelioma: 2026 Guide
Elmiron Maculopathy Vision Loss Lawsuit MDL 2973: Eligibility and Claims Guide 2026
Philips CPAP Respironics Recall Lawsuit MDL 3014: Claimant Guide 2026
Roundup Non-Hodgkin Lymphoma Lawsuit 2026: MDL Status, Eligibility, and Bayer's Settlement Waves
